Journal
EUROPEAN JOURNAL OF PHARMACOLOGY
Volume 645, Issue 1-3, Pages 108-112Publisher
ELSEVIER
DOI: 10.1016/j.ejphar.2010.07.027
Keywords
Carvone; Carveol; Carvacrol; Limonene; Single sucrose-gap; Compound action potential
Categories
Funding
- CNPq
- CAPES
Ask authors/readers for more resources
Carvone (p-mentha-6,8-dien-2-one) is a monoterpene ketone found as the main active component of various essential oils. It is obtained by distillation and occurs naturally as the enantiomers (+)- and (-)-carvone. Our group have shown that the in vivo antinociceptive activity of (-)-carvone is impaired with decreased nerve excitability. To better characterize the neuropharmacology of such a monoterpene, we investigated the profile of several carvone analogues to establish a structure-function relationship related to the compound action potential (CAP) inhibitory effect. We performed ex vivo assays to evaluate the effects of (+)- and (-)-carvone, carvacrol, (-)-carveol, and limonene on CAP characteristics using a modified single sucrose-gap method. Our results demonstrated that (-)-carvone was less potent (IC50 = 10.7 +/- 0.07 mM) in reducing nerve excitability than its enantiomer, (+)-carvone (IC50 = 8.7 +/- 0.1 mM), although they shared a similar mode of action, since their effects were partially extinguished by nerve washing and also by reduction of depolarization velocity, probably as a result of voltage-gated sodium channel blockades. In a structure-activity relationship study, we demonstrated that hydroxyl groups in the (-)-carveol and carvacrol molecules enhanced the CAP blocking-effect, while the absence of oxygen moiety in (+)-limonene resulted in the effect being almost abolished. Therefore, inhibition of CAP conduction in peripheral nerves by monoterpenes could expand our understanding concerning the pharmacology of such natural bioactive compounds. Moreover, activation or inhibition of nerve excitability with these tested monoterpenes can be achieved by altering their chemical structures, and this can lead to further implications for target-directed drug design. Crown Copyright 2010 Published by Elsevier B.V. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available